Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.

Trial Details

NCT ID

NCT05955170

Phase

PHASE2

Sponsor

Institut Curie

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

Tucatinib in Combination of Oral VP16 and trastuzumab

Locations (sample)

Clermont-Ferrand, Clermont Ferrand, France|45.77969,3.08682
Amiens, France|49.9,2.3
Avignon, France|43.94834,4.80892
Caen, France|49.18585,-0.35912
Dijon, France|47.31344,5.01391

Key Eligibility Criteria

First disease progression under tucatinib-capecitabine-trastuzumab. OR Medical contra-indication to initiate or continue capecitabine in associatio…
Age \> 18 years,
Histologically confirmed HER2+ breast carcinoma (ASCO/CAP guidelines) with archived tumor tissue available,
Have a life expectancy of at least 3 months,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →